Destiny Pharma
Ticker: DEST Exchange: AIM

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Interview with CEO, Neil Clark

Neil updates on exceptionally busy recent months for infection prevention experts Destiny:

- portfolio transformed with addition of M3, a Phase 3-ready biotherapeutic product for the prevention of C. difficile infection

- first lead product XF-73 on track to end Phase 2b trial soon, with its results in Q1 2021

- agreement with SporeGen on the preventative therapy for COVID-19

- £10.4m raised by equity placing

If trial is positive, Destiny Pharma will be well-funded with two Phase 3-ready products

Download as a PDF file
26810392321 - destiny-pharma
Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates